Idiopathic short stature in children

Area of Science:

• Pediatrics
• Endocrinology
• Genetics

Background:

• Idiopathic short stature (ISS) is diagnosed when growth failure cannot be attributed to identifiable causes.
• Individuals with ISS face social and physical disadvantages due to reduced stature.
• Natural history studies indicate untreated ISS results in significantly shorter adult heights.

Purpose of the Study:

• To evaluate the efficacy and safety of growth hormone (GH) therapy in children with ISS.
• To provide evidence supporting GH treatment despite the lack of defined biochemical criteria for ISS.
• To explore potential future therapeutic strategies for specific ISS subgroups.

Main Methods:

• Review of natural-history studies on untreated ISS.
• Analysis of numerous clinical trials, including placebo-controlled studies, on GH therapy for ISS.
• Assessment of the safety profile of recombinant human GH (rhGH) treatment.

Main Results:

• GH therapy demonstrates a strong positive effect on final adult height in children with ISS.
• The benefits of GH treatment are comparable to those observed in other non-GH-deficient conditions.
• rhGH treatment is considered relatively safe, despite its high cost.

Conclusions:

• GH treatment should be considered for children with ISS, irrespective of etiological uncertainty or diagnostic limitations.
• Further research into the specific causes of poor growth in ISS may enable personalized treatment approaches.
• Future therapies might include Insulin-like Growth Factor 1 (IGF-1) or IGF-1/IGFBP-3 combinations for specific patient subgroups.